WCN26-8232 PROMIS-29 AS A VALID AND COMPARABLE PATIENT-REPORTED OUTCOME MEASURE TO THE SF-36 IN TURKISH DIALYSIS PATIENTS

N. L. Pham(Fresenius Medical Care (Germany)), Hayriye Elbi(Ege University), Özlem Kuman Tunçel(Ege University), G. Strippoli(University of Bari Aldo Moro), Saynab Atiye(Fresenius Medical Care (Germany)), Tatiana De los Ríos(Fresenius Medical Care (Germany)), ERCAN OK(Ege University), Mirja Humpert(Fresenius Medical Care (Germany)), Krister Cromm(Humboldt-Universität zu Berlin), Manuela Stauss-Grabo(Fresenius Medical Care (Germany)), Gülay Aşçı(Ege University)
Kidney International Reports
March 25, 2026
10.1016/j.ekir.2026.104138
Cited by 0

Related Papers

Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure
|New England Journal of Medicine|2023|287
Controversies and problems of volume control and hypertension in haemodialysis
|The Lancet|2016|73
Benefits and harms of high-dose haemodiafiltration versus high-flux haemodialysis: the comparison of high-dose haemodiafiltration with high-flux haemodialysis (CONVINCE) trial protocol
|BMJ Open|2020|67
The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration
|Kidney International|2024|48
CONVINCE in the context of existing evidence on haemodiafiltration
|Nephrology Dialysis Transplantation|2022|28